
Gossamer Bio Announces Topline Results for Phase 3 PROSERA Study of Seralutinib in PAH
Gossamer Bio Reports Mixed Results for Seralutinib in PAH, Demonstrates Strong Efficacy in High-Risk Subgroups Is the current landscape of pulmonary arterial hypertension (PAH) treatments failing to meet the needs of high-risk patients? Gossamer Bio, Inc. a biopharmaceutical company focused…










